Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “breast cancer”

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel ChemotherapyTerminated
NCT05747794Phase 2, Phase 3Updated Jul 30, 2026
Sponsor: Immutep S.A.S.
Breast Carcinoma
United States, Belgium, Georgia, Moldova, Spain
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruiting
NCT07285044Phase 2Updated Jul 30, 2026
Sponsor: Mayo Clinic
Amyloidosis · Basal Cell Carcinoma · Biliary Tract Carcinoma · Bladder Carcinoma
United States
Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast CancerCompleted
NCT04761055NAUpdated Jul 30, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Screening
United States
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruiting
NCT06380751Phase 3Updated Jul 30, 2026
Sponsor: AstraZeneca
Advanced Breast Cancer
United States, Argentina, Australia, Austria, Brazil +24 more
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive Not Recruiting
NCT05891171Phase 1Updated Jul 30, 2026
Sponsor: Arcus Biosciences, Inc.
Advanced Cancer · Advanced Malignancies · Bladder Cancer · Cervical Cancer
United States, Australia, Taiwan
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)Recruiting
NCT06959537Phase 1Updated Jul 30, 2026
Sponsor: M.D. Anderson Cancer Center
Breast Cancer
United States
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After SurgeryCompleted
NCT02654119Phase 2Updated Jul 30, 2026
Sponsor: University of Nebraska
HER2 Positive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
United States
African Cancer Genome: GMDCompleted
NCT05754658N/AUpdated Jul 30, 2026
Sponsor: Fox Chase Cancer Center
Breast Cancer · Prostate Cancer
United States
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)Active Not Recruiting
NCT06136897Phase 2Updated Jul 30, 2026
Sponsor: National Cancer Institute (NCI)
Malignant Solid Neoplasm
United States
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceRecruiting
NCT06830720N/AUpdated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Breast Neoplasms
Austria, Germany
Prevention of Frailty With Fisetin and Exercise in Breast Cancer SurvivorsRecruiting
NCT06113016Phase 2Updated Jul 30, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · Early Stage Breast Carcinoma
United States
Tumor-Derived FGF19Completed
NCT06068257N/AUpdated Jul 30, 2026
Sponsor: University of Central Florida
Colorectal Cancer · Breast Cancer · Healthy
United States
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerActive Not Recruiting
NCT07196774Phase 3Updated Jul 30, 2026
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Early-stage or Locally Advanced HER2-positive Breast Cancer
China
Promoting Active Living Among People With Metastatic Breast CancerRecruiting
NCT07238023NAUpdated Jul 30, 2026
Sponsor: University of Oklahoma
Metastatic Invasive Breast Cancer
United States
Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST CancerRecruiting
NCT07070128N/AUpdated Jul 29, 2026
Sponsor: AstraZeneca
Breast Neoplasms
Brazil
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruiting
NCT06562192Phase 1Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Pancreatic Ductal Adenocarcinoma · Non-small Cell Lung Cancer · HR+/HER2- Ductal and Lobular Breast Cancer · Triple Negative Breast Cancer
United States, Belgium, Canada, France, Germany +5 more
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast CancerRecruiting
NCT04889924NAUpdated Jul 29, 2026
Sponsor: Hospital Universitari de Bellvitge
Breast Cancer · Chemotherapy · Sentinel Lymph Node · Axillary Lymph Nodes Dissection
Australia, Spain
Ultrahypofractionated Versus Normofractionated Sequential Boost After Whole-breast Radiation Therapy in Patients Treated With Breast-conserving Surgery for Breast CancerCompleted
NCT07590505Phase 3Updated Jul 29, 2026
Sponsor: Cancer Research Antwerp
Breast Cancer
Belgium
Culmerciclib in HR+/HER2+ Advanced Breast CancerRecruiting
NCT07732491Phase 2Updated Jul 29, 2026
Sponsor: Sun Yat-sen University
Breast Cancer · Metastastic Breast Cancer · HER2+ Advanced Breast Cancer
China
Rash & Diarrhea Prophylaxis With CapivasertibRecruiting
NCT07426822Phase 2Updated Jul 29, 2026
Sponsor: Maryam Lustberg
Metastatic HR+/HER2- Breast Cancer
United States
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive Not Recruiting
NCT06445400Phase 2Updated Jul 29, 2026
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
HER2-positive Breast Cancer
China
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast CancerCompleted
NCT06075758N/AUpdated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Jordan, Oman, United Arab Emirates
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical TrialRecruiting
NCT06802172NAUpdated Jul 29, 2026
Sponsor: Fred Hutchinson Cancer Center
Rectal Cancer Stage II · Rectal Cancer Stage III · Breast Cancer Stage I · Rectal Cancer Stage IV
United States
Genetic Assessment of Breast Cancer Risk in Women in the DORA ProgrammeRecruiting
NCT07734389NAUpdated Jul 29, 2026
Sponsor: Institute of Oncology Ljubljana
Breast Cancer · Breast Cancer Risk
Slovenia
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastActive Not Recruiting
NCT03304080Phase 1, Phase 2Updated Jul 29, 2026
Sponsor: Icahn School of Medicine at Mount Sinai
Breast Neoplasms · Breast Diseases
United States

Previous page Next page